Effective treatment of drug safety: A Synthesis of Findings from 25 Studies

  1. Home
  2. Effective treatment of drug safety
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of drug safety: A Synthesis of Findings from 25 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of drug safety: A Synthesis of Findings from 25 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Findings

A collection of research articles provide insights into the safety and effectiveness of various medications. For instance, 1 delves into the safety evaluation of bimekizumab treatment for moderate to severe plaque psoriasis. Another study, 2 , focuses on atypical dyskinesias observed during antipsychotic drug treatment. 3 investigates the association between long-term use of ACE inhibitors and lung cancer. 4 examines drug safety for COVID-19 treatment prior to conception, during pregnancy, and breastfeeding. 5 explores the safety and efficacy of selexipag as an add-on treatment for children with pulmonary arterial hypertension. Finally, 6 evaluates the clinical efficacy and drug safety of rivaroxaban for preventing and treating thromboembolic diseases in elderly individuals.

Treatment Summary

1 focuses on bimekizumab treatment for moderate to severe plaque psoriasis. This treatment works by neutralizing both IL-17A and IL-17F. 4 highlights the use of various medications to combat COVID-19 infection. It emphasizes the crucial need to select drugs carefully, considering potential risks to pregnant or breastfeeding women. 7 examines the integration of drug safety monitoring within tuberculosis treatment programs. It underscores the importance of early detection and management of adverse events related to tuberculosis medications.

Benefits and Risks

Benefit Summary

These research papers suggest that certain medications offer both effectiveness and safety for specific conditions. For example, bimekizumab shows promise as a treatment for moderate to severe plaque psoriasis. Rivaroxaban has been deemed an effective and safe medication for preventing and treating thromboembolic diseases in elderly individuals. These studies also highlight the importance of drug safety monitoring.

Risk Summary

Conversely, these studies also discuss the potential side effects associated with various medications. For instance, antipsychotic drugs may lead to atypical dyskinesias. Long-term ACE inhibitor use could potentially increase the risk of lung cancer. Pregnant or breastfeeding women must carefully consider the risk of side effects when using medications for COVID-19 treatment.

Study Comparison

Commonalities

These research papers share a common goal: evaluating the safety and effectiveness of medications. Each study focuses on a particular disease or treatment approach, offering insights and knowledge within its specific field.

Differences

The individual research papers differ in terms of their target conditions, treatment approaches, and study designs. For example, 1 focuses on the safety evaluation of bimekizumab treatment for psoriasis, while 2 examines atypical dyskinesias observed during antipsychotic drug therapy. These studies, while addressing drug safety, explore distinct aspects of medication use.

Consistency and Contradictions

Due to variations in study subjects and designs, there are instances of consistency and contradictions in the results. For instance, 3 suggests a potential link between long-term ACE inhibitor use and increased lung cancer risk, whereas other studies may not show the same correlation. Further investigation is needed to clarify such discrepancies.

Real-World Application Considerations

Applying these research findings to real-life situations demands caution. It is essential to remember that each study was conducted under specific conditions and results might not be universally applicable. Moreover, individual responses to medication vary. Therefore, consulting a physician to select the most suitable treatment option is crucial.

Limitations of Current Research

These research papers have limitations. For example, some studies may involve a limited number of participants, have short follow-up durations, or potentially be subject to biases. These limitations should be considered when interpreting the results.

Future Research Directions

Many questions remain unanswered in the research presented. For example, we need further investigation into the long-term effects of specific medications and the impact of combining different medications. Addressing these questions requires ongoing research.

Conclusion

These research papers provide valuable insights into the safety and effectiveness of various medications. It is essential for patients to discuss their treatment options with their physicians and make informed decisions. Further research will continue to deepen our understanding of medications and their impact on health.

Treatment List

Bimekizumab treatment, Antipsychotic drug treatment, ACE inhibitor treatment, COVID-19 treatment, Tuberculosis treatment, Rivaroxaban treatment

Literature analysis of 25 papers
Positive Content
22
Neutral Content
1
Negative Content
2
Article Type
0
1
0
18
25
1.

Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.

Author: RuggieroAngelo, PotestioLuca, MartoraFabrizio, VillaniAlessia, ComuneRosita, MegnaMatteo

Psoriasis treatment

This article reviews interleukin (IL)-17 inhibitors, a class of biologic therapies for moderate-to-severe psoriasis. The article focuses on bimekizumab, the newest IL-17 inhibitor, which neutralizes both IL-17A and IL-17F and has a unique mechanism of action compared to other IL-17 inhibitors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project.

Author: BaumgärtnerJessica, GrohmannRenate, BleichStefan, GlockerCatherine, SeifertJohanna, TotoSermin, RütherEckart, EngelRolf R, StübnerSusanne

Atypical dyskinesias

This study aimed to describe atypical dyskinesias (AtypDs) occurring during treatment with antipsychotic drugs (APDs). AtypDs are dyskinesias with unusual temporal relationships or clinical presentations.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Modest Association of Long-Term ACE Inhibitor Treatment With Lung Cancer: The Promise and Pitfalls of Epidemiological Drug-Safety Analyses.

Author: FairmanKathleen A

ACE inhibitor treatment
Heart failure
Lung cancer

This article discussed the results of the ERACER study, which investigated the association of long-term angiotensin-converting enzyme (ACE) inhibitor use with incident lung cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
CommentA short article/note that provides an opinion/perspective/interpretation on a published paper/topic.

Language : English

4.

COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.

Author: CavalcanteMarcelo Borges, CavalcanteCandice Torres de Melo Bezerra, BragaAna Catherine Sampaio, AndradeDennyse Araújo, MontenegroMariana Albuquerque, SantosPaula Andrade Neiva, MotoyamaPaula Vitória Pereira, RochaMarcelo Gondim, DibLuciana Azôr, Araujo JúniorEdward

Anti-COVID-19 therapy safety
COVID-19 treatment research

COVID-19 is a viral respiratory infection that has spread globally and can have severe consequences, especially for the elderly and those with chronic diseases. While most cases present with mild flu-like symptoms, some require intensive care. There is currently no specific treatment for COVID-19, and the safety of anti-COVID-19 therapies during pregnancy and breastfeeding requires further investigation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.

Author: HansmannGeorg, MeinelKatharina, BukovaMila, ChouvarinePhilippe, WåhlanderHåkan, KoestenbergerMartin,

Disease progression prevention
PAH improvement
RV function improvement
Death
Lung transplant

An observational study of 15 children with pulmonary arterial hypertension (PAH) found that add-on selexipag therapy, an oral prostacyclin receptor agonist, was well tolerated and safe. Selexipag improved several outcome-relevant variables in about 50% of patients and prevented disease progression in an additional 27%.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

Author: TiemersmaEdine, van den HofSusan, DravnieceGunta, WaresFraser, MollaYohannes, PermataYusie, LukitosariEndang, QuelapioMamel, AungSi Thu, AungKhay Mar, ThuyHoang Thanh, HoaVu Dinh, SulaimanovaMerkinai, SagyndikovaSaadat, MakhmudovaMavluda, SolievAlijon, KimerlingMichael

AE awareness
DR-TB treatment
AEs
DR-TB

New drugs are available for drug-resistant tuberculosis (DR-TB), and active pharmacovigilance (PV) is important for monitoring their safety. This review examines PV for DR-TB and discusses the need for increased PV capacity and collaboration between national TB programs and national PV centers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.

Author: CastellanPietro, CastellucciRoberto, MarchioniMichele, De NunzioCosimo, TemaGiorgia, PrimiceriGiulia, SchipsLuigi, CindoloLuca

Prostate cancer treatment
Quality of life
Hepatotoxicity
Mineralocorticoid AEs

This literature review examines the safety profile of abiraterone acetate (AA) in treating metastatic prostate cancer (mPCa). The review found that AA is generally well-tolerated and effective, particularly in asymptomatic or minimally symptomatic patients. However, known toxicities like mineralocorticoid- and corticosteroid-related adverse events and hepatotoxicity require careful monitoring.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Mining clinical big data for drug safety: Detecting inadequate treatment with a DNA sequence alignment algorithm.

Author: LedieuThibault, BouzilleGuillaume, PlaisantCatherine, ThiessardFrantz, PolardElisabeth, CuggiaMarc

Drug safety improvement

This study developed a visual analytics tool for health data mining, using a modified Smith-Waterman algorithm to identify specific clinical event sequences in electronic health records. This tool can be used for pharmacovigilance activities, such as detecting inadequate treatment decisions in patient sequences.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis.

Author: LipingZeng, XiufangLiu, TaoYang, BaominZhao, HoushuaiTuo

Atherosclerosis treatment
Atheromatous plaque

This study found that rosuvastatin was more effective than atorvastatin in lowering serum lipid levels and improving peripheral atherosclerosis. Rosuvastatin also reversed atherosclerotic plaques more effectively than atorvastatin and did not increase the risk of adverse reactions.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.

Author: MauriM C, ReggioriA, PalettaS, Di PaceC, AltamuraA C

Schizophrenia treatment
Hyperprolactinemia
Parkinsonism

This review examines the safety and tolerability of paliperidone, a second-generation antipsychotic, for treating schizophrenia. Paliperidone is available in extended-release oral and long-acting injectable formulations. While generally well-tolerated, potential side effects include hyperprolactinemia and parkinsonism.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Tiotropium for the treatment of asthma: a drug safety evaluation.

Author: KerstjensHuib A M, O'ByrnePaul M

This review summarizes the safety data from published clinical trials of tiotropium, a long-acting anticholinergic bronchodilator, for the treatment of asthma.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.

Author: RoglianiPaola, CalzettaLuigino, CazzolaMario, MateraMaria Gabriella

Roflumilast effective
Back pain
Gastrointestinal AEs
Headache
Insomnia

This review assessed the safety and efficacy of roflumilast, a phosphodiesterase 4 inhibitor approved for COPD. Roflumilast increased the risk of adverse events, especially gastrointestinal, but did not impact the risk of serious adverse events. Roflumilast may be beneficial for patients with a high risk of severe exacerbations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.

Author: PonzianiFrancesca Romana, PecereSilvia, LopetusoLoris, ScaldaferriFranco, CammarotaGiovanni, GasbarriniAntonio

Gut microbiota modulation

Gut microbiota modulation by non-absorbable antibiotics is a potential therapeutic option for patients with Irritable Bowel Syndrome (IBS). This approach targets the multifactorial etiology of IBS, which includes alterations of intestinal motility and immunity, gut-brain interactions, and gut microbiota dysbiosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

17.

Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.

Author: YabeDaisuke, SeinoYutaka

Improved glycemic control
Reduced risk of hypoglycemia
Reduced risk of weight gain

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as alogliptin, are increasingly used to treat type 2 diabetes (T2DM) due to their ability to improve glycemic control without increasing the risk of hypoglycemia or weight gain. This abstract emphasizes the need for new therapies with improved safety profiles for T2DM.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Drug safety in acute migraine treatment.

Author: TajtiJános, MajláthZsófia, SzokDélia, CsátiAnett, VécseiLászló

Cardiovascular side effects
Gastrointestinal side effects
Medication overuse headache

The use of analgesics, ergot alkaloids, and triptans for acute migraine treatment is limited by their safety profiles and potential adverse effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.

Author: TafiEmanuela, ScalaCarolina, Leone Roberti MaggioreUmberto, BizzarriNicolò, CandianiMassimo, VenturiniPier Luigi, FerreroSimone

Leiomyoma treatment
Progesterone antagonist

Ulipristal acetate, a new type of drug, shows potential in treating uterine fibroids. It effectively blocks the effects of progesterone, the hormone responsible for fibroid growth.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

20.

Drug safety and tolerability in prophylactic migraine treatment.

Author: VécseiLászló, MajláthZsófia, SzokDélia, CsátiAnett, TajtiJános

Migraine prevention
Cardiovascular events
Central nervous system side effects
Depression
Weight gain

This review discusses prophylactic treatment options for migraine, focusing on potential adverse effects and safety issues. Beta-blockers, antiepileptic drugs, and calcium-channel blockers are commonly used, but side effects can limit their use. Complementary medicine and onabotulinumtoxin A may be suitable in specific cases.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.

Author: BarnettAnthony H

Improved glycemic control
Lower hypoglycemia risk
No weight gain
CV events
Pancreatitis

Linagliptin, a dipeptidyl peptidase-4 inhibitor, is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). It improves glycemic control without increasing the risk of hypoglycemia or causing weight gain. It may be a rational alternative treatment option for patients with renal impairment, as it can be used without dose titration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.

Author: VerpeutJessica L, BelloNicholas T

Obesity treatment

The combination of naltrexone and bupropion, while not effective individually for obesity, may offer a promising therapeutic approach for weight loss and metabolic improvements in individuals with obesity.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.

Author: HuillardOlivier, BoissierEmilie, BlanchetBenoit, Thomas-SchoemannAudrey, CessotAnatole, Boudou-RouquettePascaline, DurandJean-Philippe, CoriatRomain, GirouxJulie, AlexandreJerome, VidalMichel, GoldwasserFrancois

Renal cancer treatment
Acute toxicity

Sorafenib is a multi-tyrosine kinase inhibitor used in treating metastatic renal cancer. While the management of early toxicity is established, the management of prolonged treatment poses a new challenge.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

Drug safety evaluation of vemurafenib in the treatment of melanoma.

Author: TsaiKenneth Y, NowrooziSasan, KimKevin B

Vemurafenib for melanoma
Vemurafenib skin toxicity

Vemurafenib, a targeted therapy for V600 BRAF-mutant advanced melanoma, has shown a clinical response rate of approximately 50% and a median progression-free survival duration of 6-7 months. While vemurafenib does not induce life-threatening toxicity frequently associated with conventional chemotherapy, it is associated with skin toxicities.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

25.

Drug safety evaluation of maraviroc for the treatment of HIV infection.

Author: WasmuthJan-Christian, RockstrohJürgen Kurt, HardyWilliam David

HIV treatment
Safe and well tolerated
Long term risks unknown

Maraviroc is a generally safe and well-tolerated medication for the treatment of HIV-1 infection with a unique mechanism of action. Long-term (i.e., > 5 years) risks are not known and have to be carefully monitored.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.